Frazor III - Zai Lab Chief Sec
| ZLAB Stock | USD 28.09 1.66 6.28% |
Insider
Frazor III is Chief Sec of Zai Lab
| Age | 58 |
| Address | Jinchuang Plaza, Shanghai, China, 201210 |
| Phone | 86 21 6163 2588 |
| Web | https://www.zailaboratory.com |
Zai Lab Management Efficiency
The company has return on total asset (ROA) of (0.2083) % which means that it has lost $0.2083 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3498) %, meaning that it created substantial loss on money invested by shareholders. Zai Lab's management efficiency ratios could be used to measure how well Zai Lab manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.34. In addition to that, Return On Capital Employed is expected to decline to -0.46. At present, Zai Lab's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 17.3 M, whereas Total Assets are forecasted to decline to about 754.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Huafeng Xu | Roivant Sciences | N/A | |
| Piyush JD | Alnylam Pharmaceuticals | N/A | |
| Jonathan MD | Erasca Inc | 52 | |
| Tracey Esq | Blueprint Medicines Corp | 56 | |
| Kelly Schick | C4 Therapeutics | 44 | |
| Ellen Welch | PTC Therapeutics | N/A | |
| Lisa TesvichBonora | Erasca Inc | N/A | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Jens Okkels | Ascendis Pharma AS | 63 | |
| Richard Pulik | Roivant Sciences | 44 | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| David Glynn | Krystal Biotech | N/A | |
| MS MBA | Krystal Biotech | 59 | |
| Matthew Gline | Roivant Sciences | 40 | |
| Jacquelyn JD | Cullinan Oncology LLC | 46 | |
| William JD | Akero Therapeutics | 51 | |
| Gloria Lin | Krystal Biotech | N/A | |
| Rebecca MD | Madrigal Pharmaceuticals | 72 | |
| Robert Waltermire | Madrigal Pharmaceuticals | 60 | |
| Alexis AM | Blueprint Medicines Corp | 52 | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.21 |
Zai Lab Leadership Team
Elected by the shareholders, the Zai Lab's board of directors comprises two types of representatives: Zai Lab inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zai. The board's role is to monitor Zai Lab's management team and ensure that shareholders' interests are well served. Zai Lab's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zai Lab's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Huang, Chief Officer | ||
| Dr MBA, Chief Officer | ||
| Rafael MD, President Development | ||
| Joshua Smiley, Chief Officer | ||
| Frazor III, Chief Sec | ||
| Christine Chiou, Senior Relations | ||
| Harald MD, Autoimmune Neuroscience | ||
| Ann JD, Chief Officer | ||
| Ning MD, Executive Operations | ||
| DABT MD, Chief RD | ||
| Yajing Chen, Chief Officer | ||
| Alan MD, Pres Oncology | ||
| JD III, Chief Secretary | ||
| Ki Cho, Chief Officer | ||
| MBA MBA, Chief Officer | ||
| Ying Du, Chairperson Founder |
Zai Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zai Lab a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (0.76) % | ||||
| Operating Margin | (0.66) % | ||||
| Current Valuation | 2.24 B | ||||
| Shares Outstanding | 107.45 M | ||||
| Shares Owned By Insiders | 1.96 % | ||||
| Shares Owned By Institutions | 44.39 % | ||||
| Number Of Shares Shorted | 4.66 M | ||||
| Price To Book | 4.25 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zai Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zai Lab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zai Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zai Lab Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zai Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Zai Stock refer to our How to Trade Zai Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zai Lab. If investors know Zai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zai Lab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.80) | Revenue Per Share 3.647 | Quarterly Revenue Growth 0.477 | Return On Assets (0.21) | Return On Equity (0.35) |
The market value of Zai Lab is measured differently than its book value, which is the value of Zai that is recorded on the company's balance sheet. Investors also form their own opinion of Zai Lab's value that differs from its market value or its book value, called intrinsic value, which is Zai Lab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zai Lab's market value can be influenced by many factors that don't directly affect Zai Lab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zai Lab's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zai Lab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zai Lab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.